Results 11 to 20 of about 3,351 (178)

Zanubrutinib-Induced Acneiform Rash in a Patient With Waldenstrom’s Macroglobulinemia

Case Reports in Medicine
Waldenström’s macroglobulinemia is a rare lymphoproliferative disorder that can be treated with Bruton’s Tyrosine Kinase inhibitors (BTKi), including zanubrutinib.
Silvia Robuffo, Corrado Zengarini, Claudio Agostinelli, Elena Sabattini, Michelangelo La Placa, Bianca Maria Piraccini, Alessandro Pileri   +6 more
doaj   +2 more sources

Extranodal Lymphoplasmacytic Lymphoma Responding Rapidly to Zanubrutinib: A Case Series. [PDF]

Clin Case Rep
ABSTRACT Management of recurrent or atypical lymphoplasmacytic lymphoma poses a significant therapeutic challenge. Here we demonstrate a case series of three patients with atypical presentations of extranodal lymphoplasmacytic lymphoma that each show remarkable and timely responses to Zanubrutinib with a limited side effect profile.
Brown S, Rusbridge J, Follows G, Santarsieri A.   +3 more
europepmc   +2 more sources

Matching-adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed-duration venetoclax and ibrutinib in patients with treatment-naïve chronic lymphocytic leukaemia. [PDF]

Br J Haematol
British Journal of Haematology, Volume 208, Issue 1, Page 321-324, January 2026.
Munir T, Mohseninejad L, Rakonczai P, Dobi B, Xu S, Yang K, Vezan R, Calle NM.   +7 more
europepmc   +2 more sources

Successful Zanubrutinib Monotherapy in a Rare CNS Presentation of Relapsed CLL. [PDF]

Case Rep Hematol
Background Central nervous system (CNS) involvement is an infrequent complication of chronic lymphocytic leukemia (CLL), occurring in less than 1% of cases. We report a case of a 63‐year‐old male with a history of CLL previously treated with ibrutinib but discontinued early due to intolerance. As a result, the patient was then treated with obinutuzumab
Kunta V, Ammad-Ud-Din M, Mediavilla-Varela M, Pinilla-Ibarz J.   +3 more
europepmc   +2 more sources

Unmet clinical needs in the use of zanubrutinib in malignant lymphomas (Waldenström macroglobulinemia, marginal zone lymphoma and mantle cell lymphoma): A consensus‐based position paper from an ad hoc expert panel [PDF]

, 2023
Zanubrutinib has been approved for the treatment of patients with different lymphoproliferative disorders, and now represents a major breakthrough in the treatment of patients resistant or relapsing after the recommended therapies. Because few systematic
Barosi, Giovanni, Mauro, Francesca Romana, Tedeschi, Alessandra, Varettoni, Marzia, Zaja, Francesco, Zinzani, Pier Luigi   +5 more
core   +4 more sources

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors [PDF]

, 2023
No abstract ...
Calvo, Roser, Davies, Andrew J., Doorduijn, Jeanette K., Długosz-Danecka, Monika, Eek, Richard, Goy, Andre, Jacobsen, Eric, Jain, Preetesh, Kater, Arnon P., Le Gouill, Steven, Panizo, Carlos, Robak, Tadeusz, Rule, Simon, Shah, Bijal D., Smith, Stephen D., Tao, Lin, Wang, Michael, Zinzani, Pier Luigi   +17 more
core   +8 more sources

Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab [PDF]

, 2023
OBJECTIVE: Zanubrutinib is a highly selective, next-generation Bruton\u27s tyrosine kinase inhibitor. In the phase 3 SEQUOIA trial (NCT03336333), treatment with zanubrutinib resulted in significantly improved progression-free survival compared to ...
Barnes, Gisoo, Brown, Jennifer R, Ghia, Paolo, Kahl, Brad S, Paik, Jason C, Robak, Tadeusz, Shadman, Mazyar, Szeto, Andy, Tam, Constantine S, Tian, Tian, Yang, Keri   +10 more
core   +5 more sources

Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions

Frontiers in Oncology, 2023
Zanubrutinib (BGB-3111, Brukinsa®, BeiGene) is a next-generation irreversible inhibitor of Bruton’s tyrosine kinase (BTK), developed by BeiGene in 2012 for the treatment of B-cell malignancies.
Anna Wolska-Washer, Anna Wolska-Washer, Tadeusz Robak, Tadeusz Robak   +3 more
doaj   +1 more source

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option [PDF]

, 2023
Ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor (BTKi), is a commonly deployed therapeutic option for previously untreated and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia (CLL).
Allsup, David, Molica, Stefano, Polliack, Aaron, Tam, Constantine   +3 more
core   +1 more source

Case report: Zanubrutinib-induced dermatological toxicities: A single-center experience and review

Frontiers in Oncology, 2022
Zanubrutinib, a next-generation non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, shows great efficacy in the treatment of B cell malignancies. Some patients may experience a series of side effects after the treatment of zanubrutinib.
Lingling Wang, Jiao Tang, Jun Feng, Yongfen Huang, Yuexin Cheng, Hao Xu, Yuqing Miao   +6 more
doaj   +1 more source